Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ANVS
#3492
Annovis Bio, Inc.
2.6
9
-2.54%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-2.54%
Monthly Change
-9.12%
6 month change
+14.47%
Year Change
+46.20%
Previous Close
2.7
6
Open
2.6
6
Bid
Ask
Low
2.6
6
High
2.6
9
Volume
28
Markets
US Stock Market
Healthcare
ANVS
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2020
2021
2022
2023
2024
TTM
Cash from operating activities
-3.97 M
-9.13 M
-17.31 M
-39.97 M
-21.89 M
-24.98 M
Cash from investing activities
—
—
—
—
—
—
Cash from financing activities
12.04 M
46.74 M
4 613
17.34 M
26.69 M
27.63 M
Free cash flow
-3.97 M
-9.13 M
-17.31 M
-39.97 M
-21.89 M
-24.98 M
News
Annovis Bio to launch long-term Parkinson’s drug study in January
Analysis-Alzheimer’s drug hunt learns from cancer fight’s multi-target playbook
Monday’s Insider Moves: Adverum Execs Lead Buys, Diamondback Sale Tops
Annovis Bio director Hoffman buys $193,794 in shares
Sunday’s Insider Moves: Major Buys at STAA, ANVS While ROIV Sees Selling
Annovis Bio director Hoffman buys $69.9k in ANVS stock
Annovis Bio Stock Jumps On Heels Of New Parkinson's Data - Annovis Bio (NYSE:ANVS)
Annovis Bio’s phase 3 Alzheimer’s trial reaches 25% completion
Annovis Bio raises $3.4 million in registered direct offering
Annovis Bio raises $6 million in registered direct offering
Annovis Bio reports buntanetap reduces inflammation in Alzheimer’s patients
Canaccord Genuity reaffirms Buy rating on Annovis Bio stock